24 results found.

Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers.

Prostatic Neoplasms Clinical Trial using VT-122; Placebo

Vicus Therapeutics - Recruiting 18 years or older.
- A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer.
VT-122; Placebo

Prostate Cancer, Castration Resistant Prostate Cancer, Pain, or P Clinical Trial using cabozantinib; mitoxantrone; prednisone

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer.
cabozantinib; mitoxantrone; prednisone

Prostatic Neoplasms Clinical Trial using BAY2010112

Bayer - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY2010112 Given Once Daily by Subcutaneous Administration in Subjects With Castration-resistant Prostate Cancer.
BAY2010112

Prostatic Neoplasms, or Bone Mineral Density Quantitative Trait L Clinical Trial using vitamin D; Placebo

University of Rochester - Recruiting 60 years or older.
- High-dose Vitamin D Supplementation for ADT-induced Side Effects.
vitamin D; Placebo

Prostatic Neoplasms Clinical Trial

Centre Hospitalier Universitaire de NÄ«mes - Recruiting 45 years to 75 years.
- Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy.

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks.
Radium-223 dichloride (Xofigo, BAY88-8223)

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 18 years or older.
- A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Radium-223 dichloride (Xofigo, BAY88-8223)

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Prostatic Neoplasms Clinical Trial using Cabozantinib; Docetaxel; Prednisone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
Cabozantinib; Docetaxel; Prednisone

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo, BAY88-8223)

Bayer - Recruiting 20 years or older.
- A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases.
Radium-223 dichloride (Xofigo, BAY88-8223)

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (BAY88-8223)

Bayer - Recruiting 18 years or older.
- Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases.
Radium-223 dichloride (BAY88-8223)

Prostatic Neoplasms Clinical Trial using Radium-223 dichloride (Xofigo,BAY88-8223); Abiraterone acetate; Prednisone; Enzalutamide

Bayer - Recruiting 18 years or older.
- A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination With Abiraterone Acetate or Enzalutamide in Subjects With CRPC Who Have Bone Metastases.
Radium-223 dichloride (Xofigo,BAY88-8223); Abiraterone acetate; Prednisone; Enzalutamide

Prostatic Neoplasms, or Prostate Cancer Clinical Trial

Stanford University - Recruiting 18 years or older.
- Quality of Life Following Radical Prostatectomy.

Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Clinical Trial using sipuleucel-T

Dendreon - Recruiting 18 years or older.
- An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer.
sipuleucel-T

Prostatic Neoplasms, or Prostate Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies.

Prostate Cancer, or Prostatic Neoplasms Clinical Trial using Panobinostat; Bicalutamide

New York University School of Medicine - Recruiting 18 years or older.
- Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer.
Panobinostat; Bicalutamide

Prostatic Neoplasms Clinical Trial using CFG920

Novartis - Recruiting 18 years or older.
- A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer.
CFG920

Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Mela Clinical Trial using Interactive Voice Response (IVR) Reminders

Michigan State University - Recruiting 21 years or older.
- Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR.
Interactive Voice Response (IVR) Reminders

Prostate Cancer, or Prostatic Neoplasms Clinical Trial using Visualase Thermal Therapy System

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- MR Image Guided Focal Therapy in Prostate Cancer.
Visualase Thermal Therapy System

Prostate Cancer, Castration Resistant Prostate Cancer, or Prostat Clinical Trial using cabozantinib; abiraterone; prednisone

Exelixis - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Na‹ve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer.
cabozantinib; abiraterone; prednisone

Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms Clinical Trial using Bone marrow sparing IMRT radiation therapy

University of Iowa - Recruiting 18 years or older.
- Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging.
Bone marrow sparing IMRT radiation therapy

Prostatic Neoplasms, Cancer of Prostate, Prostate Cancer, or Pros Clinical Trial using Laparoscopic Radical Prostatectomy (without a simulator); Laparoscopic Radical Prostatectomy (with a simulator)

Assistance Publique - H“pitaux de Paris - Recruiting N/A or older.
- A Prospective Randomized Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Online Simulator.
Laparoscopic Radical Prostatectomy (without a simulator); Laparoscopic Radical Prostatectomy (with a simulator)

Prostatic Neoplasms Clinical Trial using Samarium Sm-153 lexidronam + Docetaxel

Cytogen Corporation - Recruiting N/A or older.
- Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer.
Samarium Sm-153 lexidronam + Docetaxel